(firstQuint)Carboplatin Periocular Injection for Retinoblastoma.

 This study will be a phase III open label interventional case series.

 Patients with retinoblastoma will be randomized to receive chemotherapy with or without periocular injections of carboplatin at a dose of 20mg/2 ml.

 Patients will receive carboplatin periocular on a monthly basis for a total duration of therapy of 6 months.

 Patients will be followed for 24 months .

.

 Carboplatin Periocular Injection for Retinoblastoma@highlight

This study will evaluate the clinical efficacy of periocular injections of carboplatin together with chemotherapy in the treatment of Retinoblastoma as compared to chemotherapy alone.

